# Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

> **NCT04670913** · PHASE2 · UNKNOWN · sponsor: **Junling Li** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Non Squamous NSCLC

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT04670913
- **Lead sponsor:** Junling Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-28
- **Primary completion:** 2021-12
- **Final completion:** 2022-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04670913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04670913, "Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04670913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*